1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Buyout talks?

Discussion in 'Healthtronics' started by Anonymous, Jan 31, 2013 at 9:05 AM.

  1. Anonymous

    Anonymous Guest

    Endo Health in Talks With Potential Buyers--Reuters

    Endo Health Solutions Inc. (ENDP) is in talks with drug makers about selling itself, Reuters reported, citing people familiar with the matter. Shares were recently 9% higher at $31.23 after tripping a single-stock circuit breaker. The stock is down 13% over the last 12 months. The exploratory talks include Warner Chilcott PLC (WCRX) and Valeant Pharmaceuticals International Inc. (VRX, VRX.T), but there is no official auction process underway and discussions are at a preliminary stage, according to the report. A representative for Endo declined to comment to Dow Jones, while Warner Chilcott and Valeant didn't immediately respond to requests for comment. Earlier this month, Endo Health lowered its 2013 guidance, saying it expects higher charges related to its core painkiller franchise and generic-drug business. Full story: http://www.reuters.com/article/2013/01/30/us-endohealth-sale-idUSBRE90T19020130130 Write to Hot Stocks at hotstocks@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires